Experimental design approach in recombinant protein expression: determining medium composition and induction conditions for expression of pneumolysin from Streptococcus pneumoniae in Escherichia coli and preliminary purification process.

BACKGROUND: Streptococcus pneumoniae (S. pneumoniae) causes several serious diseases including pneumonia, septicemia and meningitis. The World Health Organization estimates that streptococcal pneumonia is the cause of approximately 1.9 million deaths of children under five years of age each year. The large number of serotypes underlying the disease spectrum, which would be reflected in the high production cost of a commercial vaccine effective to protect against all of them and the higher level of amino acid sequence conservation as compared to polysaccharide structure, has prompted us to attempt to use conserved proteins for the development of a simpler vaccine. One of the most prominent proteins is pneumolysin (Ply), present in almost all the serotypes known at the moment, which shows an effective protection against S. pneumoniae infections. RESULTS: We have cloned the pneumolysin gene from S. pneumoniae serotype 14 and studied the effects of eight variables related to medium composition and induction conditions on the soluble expression of rPly in Escherichia coli (E. coli) and a 28-4 factorial design was applied. Statistical analysis was carried out to compare the conditions used to evaluate the expression of soluble pneumolysin; rPly activity was evaluated by hemolytic activity assay and served as the main response to evaluate the proper protein expression and folding. The optimized conditions, validated by the use of triplicates, include growth until an absorbance of 0.8 (measured at 600 nm) with 0.1 mM IPTG during 4 h at 25°C in a 5 g/L yeast extract, 5 g/L tryptone, 10 g/L NaCl, 1 g/L glucose medium, with addition of 30 µg/mL kanamycin. CONCLUSIONS: This experimental design methodology allowed the development of an adequate process condition to attain high levels (250 mg/L) of soluble expression of functional rPly in E. coli, which should contribute to reduce operational costs. It was possible to recover the protein in its active form with 75% homogeneity.

Development of a rapid and sensitive latex agglutination-based method for detection of group A rotavirus.

Considering the background of morbidity and mortality caused by human rotavirus, detection methods that use rotavirus group antigen (VP6) in either enzyme immunoassay (EIA) or latex agglutination test (LAT) has been employed routinely in clinical diagnostic and epidemiological studies. In order to develop a rapid and sensitive rotavirus group A LAT, part of segment 6 corresponding to conserved N-terminal portion of the VP6 (1-245 aa) was cloned in Escherichia coli expression pGEX vector (glutathione S-transferase-GST gene fusion system) that has been modified previously containing a histidine tail at C-terminus. The immunological propriety of the recombinant VP6 having a total molecular weight of 52 kDa was evaluated by Western blot and by the ability of inducing anti-recombinant VP6 polyclonal antibodies in rabbit. The polyclonal serum produced was conjugated to a latex support to detect rotavirus in stool specimens. The percentage values for sensitivity and specificity of the rotavirus group A LAT were 98.5% and 100%, respectively.